Study of Reduced Anti-coagulation/Anti-platelet Therapy in Patients With the HeartMate II Left Ventricular Assist System (LVAS) (TRACE)

NCT ID: NCT01477528

Last Updated: 2022-06-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

201 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-11-30

Study Completion Date

2015-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this observational study is to obtain multi-center data on HeartMate II (HMII) patients managed with reduced anticoagulation or anti-platelet regimes, and the incidence of thrombotic and bleeding adverse events associated with these regimes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anticoagulation Left Ventricular Assist Device

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HeartMate II Left Ventricular Assist Device (LVAD) patient
* Patient has signed an informed consent for data collection.
* Patient was discharged, or is being discharged, from the hospital after their initial LVAD implant surgery.
* Patient:

* at time of enrolling in study, is currently on, with the intention of being maintained on reduced anti-thrombotic therapy (RT) for chronic long-term management.

OR

\-- On or after January 1, 2011 patient was being maintained on, or had been initiated with the intention of being maintained on, reduced anti-thrombotic therapy (RT) for chronic long-term management; but where RT was subsequently discontinued due to an adverse event or transplant, explant, or death.

Exclusion Criteria

* Patients under acute management of anti-thrombotic agents before a final decision on long term antithrombotic strategy.
* Patients requiring a legal representative to sign consent form, rather than themselves.
* Patient is being managed on other anti-thrombotic agents
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Thoratec Europe Ltd

INDUSTRY

Sponsor Role collaborator

Abbott Medical Devices

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pooja Chatterjee

Role: STUDY_DIRECTOR

Thoratec Europe Limited

David Farrar, PhD

Role: STUDY_DIRECTOR

Thoratec Corporation

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sharp Memorial Hospital

San Diego, California, United States

Site Status

University of Florida (Shands)

Gainesville, Florida, United States

Site Status

Advocate Christ Hospital

Oak Lawn, Illinois, United States

Site Status

Methodist Hospital of Indiana

Indianapolis, Indiana, United States

Site Status

St. Vincent Heart Center of Indiana

Indianapolis, Indiana, United States

Site Status

University of Minnesota

Minneapolis, Minnesota, United States

Site Status

Columbia University Medical Center

New York, New York, United States

Site Status

University of North Carolina

Chapel Hill, North Carolina, United States

Site Status

Allegheny General Hospital

Pittsburgh, Pennsylvania, United States

Site Status

Medical University of Vienna

Vienna, , Austria

Site Status

IKEM

Prague, , Czechia

Site Status

Service de Chirurgie Cardiaque

Grenoble, , France

Site Status

Hopital Cardiologique

Lille, , France

Site Status

Chirurgie Thoracique et Cardiovasculaire Groupe hospitalier Pitie-Salpetriere

Paris, , France

Site Status

Hôpital Pontchaillou

Rennes, , France

Site Status

Charles Nicolle University Hospital

Rouen, , France

Site Status

University of Freiburg Medical Center

Freiburg im Breisgau, , Germany

Site Status

Medical University Hannover

Hanover, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Austria Czechia France Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TC-081611

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

HeartMate 3 ELEVATE™ Registry
NCT02497950 COMPLETED
The TRICURE First in Human Trial
NCT05126030 ACTIVE_NOT_RECRUITING NA
TRISCEND II Pivotal Trial
NCT04482062 ACTIVE_NOT_RECRUITING NA